×
About 74,476 results

ALLMedicine™ Lymphoma Center

Research & Reviews  35,459 results

Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell ly...
https://doi.org/10.1111/ejh.13606
European Journal of Haematology; Zduniak A, Mihailescu SD et. al.

Feb 24th, 2021 - We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive ...

Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread.
https://doi.org/10.1186/s12977-021-00550-8 10.1073/pnas.77.12.7415 10.1038/sj.onc.1208980 10.1182/blood.V50.3.481.481 10.3389/fmicb.2017.01425/full 10.1016/S0140-6736(85)92734-5 10.1016/S0140-6736(86)91298-5 10.1038/294268a0 10.1002/ijc.2910330202 10.1002/ijc.2910430618 10.1073/pnas.1521629112 10.1038/nrdp.2015.12 10.1186/s12977-018-0454-x 10.1186/s12889-016-3366-5 10.1016/S0140-6736(18)30974-7 10.1073/pnas.1009635107 10.3390/v8030074 10.3389/fimmu.2018.00260/full 10.1038/s41598-018-29391-w 10.1126/science.6316502 10.1128/JCM.30.4.905-910.1992 10.1128/JVI.75.18.8461-8468.2001 10.1128/JVI.01799-15 10.1016/j.virusres.2019.197653 10.1111/j.1749-6632.2011.06304.x 10.1128/JVI.06993-11 10.1038/nm.2065 10.1182/blood-2004-07-2850 10.1074/jbc.M502639200 10.1182/blood-2008-03-136770 10.3389/fmicb.2019.02147 10.3389/fmicb.2016.01765 10.1089/dna.2017.3639 10.3389/fcimb.2018.00362 10.1074/jbc.A117.793521 10.3390/v9070176 10.1186/s40169-018-0204-7 10.1038/s41598-017-17765-5 10.1007/s11481-019-09865-y 10.4161/auto.5222 10.1007/s13238-014-0104-6 10.1074/jbc.M113.515361 10.1371/journal.ppat.1005018 10.1523/JNEUROSCI.3207-14.2015 10.1038/onc.2013.552 10.1038/s41598-017-08736-x 10.1016/j.cellsig.2013.09.010 10.3389/fmicb.2016.00139 10.1074/jbc.M114.549659 10.1074/jbc.M112.438895 10.1074/jbc.M115.662171 10.1073/pnas.1521230113 10.1098/rstb.2016.0479 10.1038/s41556-018-0049-8 10.1158/0008-5472.CAN-10-4455 10.1186/s12964-015-0086-x 10.1172/JCI87105 10.3389/fendo.2017.00194/full 10.1016/j.immuni.2013.10.020 10.1016/j.cell.2010.01.028 10.1016/j.virol.2015.03.042 10.1186/1755-1536-4-21 10.1038/s41598-017-17765-5 10.3389/fcimb.2020.00006 10.1111/aji.12860 10.1038/nri3831 10.1038/nri.2016.95 10.1242/jcs.154906 10.1186/s12977-016-0307-4 10.1016/j.cell.2010.02.015 10.1080/13547500701791719 10.1084/jem.20081165 10.1681/ASN.2011111077 10.1038/ncomms1180 10.3389/fimmu.2018.01463 10.3389/fimmu.2018.00534 10.1586/1744666X.2014.894886 10.1016/j.ctrv.2017.08.004 10.1155/2019/6252138 10.1016/j.jid.2018.06.188 10.1007/s12020-012-9839-0 10.3389/fmicb.2012.00378 10.1128/JVI.02147-12 10.1007/s11060-013-1084-8 10.1038/s41556-018-0250-9 10.1128/JCM.38.11.4049-4057.2000 10.1016/S1386-6532(99)00087-6 10.1084/jem.177.6.1567 10.1073/pnas.95.13.7568 10.1086/317932 10.1080/135502802317247811 10.1371/journal.ppat.1002480 10.1371/journal.ppat.1007589 10.3390/ijms20061445 10.1182/blood-2010-11-321364 10.5045/br.2017.52.2.106 10.3389/fmicb.2017.02563 10.1016/j.tins.2005.06.008 10.1161/STROKEAHA.107.513150 10.3389/fncel.2018.00494/full
Retrovirology Pinto DO, Al Sharif S et. al.

Feb 24th, 2021 - The Human T-cell Lymphotropic Virus Type-1 (HTLV-1) is a blood-borne pathogen and etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1 has currently infected up ...

IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macro...
https://doi.org/10.1136/bcr-2020-240242
BMJ Case Reports; Yang Y, Canepa C

Feb 24th, 2021 - A previously fit and well 76-year-old man, presented with distal lower limb sensory symptoms suggestive of peripheral sensory neuropathy, associated with positive anti-MAG antibodies (myelin associated glycoprotein) and IgM paraprotein. Bone marro...

Markers of Follicular Helper T Cells Are Occasionally Expressed in T-Cell or Histiocyte...
https://doi.org/10.1093/ajcp/aqaa249
American Journal of Clinical Pathology; Abukhiran I, Syrbu SI et. al.

Feb 24th, 2021 - Follicular helper T cell (TFH) markers are expressed in angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma of the TFH phenotype (PTCL-TFH). However, differential expression and coexpression of these markers in benign and othe...

see more →

Guidelines  107 results

FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma
https://www.fda.gov/drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
FDA

Jul 23rd, 2020 - The Food and Drug Administration granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed ...

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S

Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA

Apr 20th, 2020 - The Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 11th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

see more →

Drugs  111 results see all →

Clinicaltrials.gov  36,709 results

Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/treatment-with-loxo-305-results-in-durable-efficacy-in-heavily-pretreated-patients-with-cllsll/

Feb 24th, 2021 - Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s...

Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/overcoming-cd58-loss-may-be-promising-path-to-overcoming-resistance-to-car-t-cell-therapies/

Feb 24th, 2021 - Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell ther...

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/zuma-5-axicabtagene-ciloleucel-elicits-response-in-indolent-non-hodgkin-lymphoma/

Feb 24th, 2021 - In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & E...

Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell ly...
https://doi.org/10.1111/ejh.13606
European Journal of Haematology; Zduniak A, Mihailescu SD et. al.

Feb 24th, 2021 - We conducted a retrospective study to analyze the prognostic factors impacting the overall survival (OS) and progression-free survival (PFS) of diffuse large B cell lymphoma (DLBCL) patients undergoing first-line therapy and admitted to intensive ...

Extracellular vesicles from HTLV-1 infected cells modulate target cells and viral spread.
https://doi.org/10.1186/s12977-021-00550-8 10.1073/pnas.77.12.7415 10.1038/sj.onc.1208980 10.1182/blood.V50.3.481.481 10.3389/fmicb.2017.01425/full 10.1016/S0140-6736(85)92734-5 10.1016/S0140-6736(86)91298-5 10.1038/294268a0 10.1002/ijc.2910330202 10.1002/ijc.2910430618 10.1073/pnas.1521629112 10.1038/nrdp.2015.12 10.1186/s12977-018-0454-x 10.1186/s12889-016-3366-5 10.1016/S0140-6736(18)30974-7 10.1073/pnas.1009635107 10.3390/v8030074 10.3389/fimmu.2018.00260/full 10.1038/s41598-018-29391-w 10.1126/science.6316502 10.1128/JCM.30.4.905-910.1992 10.1128/JVI.75.18.8461-8468.2001 10.1128/JVI.01799-15 10.1016/j.virusres.2019.197653 10.1111/j.1749-6632.2011.06304.x 10.1128/JVI.06993-11 10.1038/nm.2065 10.1182/blood-2004-07-2850 10.1074/jbc.M502639200 10.1182/blood-2008-03-136770 10.3389/fmicb.2019.02147 10.3389/fmicb.2016.01765 10.1089/dna.2017.3639 10.3389/fcimb.2018.00362 10.1074/jbc.A117.793521 10.3390/v9070176 10.1186/s40169-018-0204-7 10.1038/s41598-017-17765-5 10.1007/s11481-019-09865-y 10.4161/auto.5222 10.1007/s13238-014-0104-6 10.1074/jbc.M113.515361 10.1371/journal.ppat.1005018 10.1523/JNEUROSCI.3207-14.2015 10.1038/onc.2013.552 10.1038/s41598-017-08736-x 10.1016/j.cellsig.2013.09.010 10.3389/fmicb.2016.00139 10.1074/jbc.M114.549659 10.1074/jbc.M112.438895 10.1074/jbc.M115.662171 10.1073/pnas.1521230113 10.1098/rstb.2016.0479 10.1038/s41556-018-0049-8 10.1158/0008-5472.CAN-10-4455 10.1186/s12964-015-0086-x 10.1172/JCI87105 10.3389/fendo.2017.00194/full 10.1016/j.immuni.2013.10.020 10.1016/j.cell.2010.01.028 10.1016/j.virol.2015.03.042 10.1186/1755-1536-4-21 10.1038/s41598-017-17765-5 10.3389/fcimb.2020.00006 10.1111/aji.12860 10.1038/nri3831 10.1038/nri.2016.95 10.1242/jcs.154906 10.1186/s12977-016-0307-4 10.1016/j.cell.2010.02.015 10.1080/13547500701791719 10.1084/jem.20081165 10.1681/ASN.2011111077 10.1038/ncomms1180 10.3389/fimmu.2018.01463 10.3389/fimmu.2018.00534 10.1586/1744666X.2014.894886 10.1016/j.ctrv.2017.08.004 10.1155/2019/6252138 10.1016/j.jid.2018.06.188 10.1007/s12020-012-9839-0 10.3389/fmicb.2012.00378 10.1128/JVI.02147-12 10.1007/s11060-013-1084-8 10.1038/s41556-018-0250-9 10.1128/JCM.38.11.4049-4057.2000 10.1016/S1386-6532(99)00087-6 10.1084/jem.177.6.1567 10.1073/pnas.95.13.7568 10.1086/317932 10.1080/135502802317247811 10.1371/journal.ppat.1002480 10.1371/journal.ppat.1007589 10.3390/ijms20061445 10.1182/blood-2010-11-321364 10.5045/br.2017.52.2.106 10.3389/fmicb.2017.02563 10.1016/j.tins.2005.06.008 10.1161/STROKEAHA.107.513150 10.3389/fncel.2018.00494/full
Retrovirology Pinto DO, Al Sharif S et. al.

Feb 24th, 2021 - The Human T-cell Lymphotropic Virus Type-1 (HTLV-1) is a blood-borne pathogen and etiological agent of Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). HTLV-1 has currently infected up ...

see more →

News  2,007 results

Burkitt Lymphoma Prognostic Index May Lead to More Targeted Therapy
https://www.medscape.com/viewarticle/945454

Feb 8th, 2021 - NEW YORK (Reuters Health) - An international team has developed and validated a prognostic index specific for Burkitt lymphoma to aid in risk stratification, interpretation of clinical trials, and targeted development of novel therapeutic strategi...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

First CAR T-cell Therapy for Mantle Cell Lymphoma Fills Unmet Need
https://www.medscape.com/viewarticle/943428

Dec 30th, 2020 - The US Food and Drug Administration (FDA) granted accelerated approval on July 24, 2020, for the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cel...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

see more →

Patient Education  83 results see all →